+91-98 455 710 46 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
15 Sep 2020

Case Study – Strategic Insight on Gilead and Immunomedics $21 Billion Deal

Posted By

Gilead Sciences Inc. agreed to acquire Immunomedics Inc. for about $21 billion, a substantial premium for the maker of a promising breast-cancer therapy, and another big bet by Gilead that an innovative tumor-fighting drug can boost its fortunes.

Why Gilead acquired Immunomedics?

  • Immunomedics Inc. develop breast-cancer treatment called Trodelvy that gained approval from the U.S.
  • TRODELVY (sacituzumab govitecan-hziy) is indicated for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies for metastatic disease.
  • This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
  • Immunomedics is having some early stage pipeline, but this deal largely on Trodelvy. 
  • Trodelvy is the first FDA-approved anti-TROP agent in April, with an initial green light in third-line metastatic triple-negative breast cancer.

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests